2. Francis A, Johnson DW, Teixeira-Pinto A, Craig JC, Wong G. 2018; Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study. Nephrol Dial Transplant. 33:881–9. DOI:
10.1093/ndt/gfx356. PMID:
29342279.
3. Park H, Kim JS, Kong JH, Kim SH, Park SW, Song SH, et al. 2016; Post-transplant lymphoproliferative disorder in transplanted kidney causing urinary tract obstruction. J Korean Soc Transplant. 30:44–9. DOI:
10.4285/jkstn.2016.30.1.44.
4. Kim B, Kang M, Kim Y, Lee HS, Kim B, Lee JJ, et al. 2021; De novo cancer incidence after kidney transplantation in South Korea from 2002 to 2017. J Clin Med. 10:3530. DOI:
10.3390/jcm10163530. PMID:
34441826. PMCID:
PMC8396914.
5. San-Juan R, Comoli P, Caillard S, Moulin B, Hirsch HH, Meylan P. 2014; Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients. Clin Microbiol Infect. 20 Suppl 7:109–18. DOI:
10.1111/1469-0691.12534. PMID:
24475976.
6. Yabu JM, Winkelmayer WC. 2011; Posttransplantation anemia: mechanisms and management. Clin J Am Soc Nephrol. 6:1794–801. DOI:
10.2215/CJN.01190211. PMID:
21734096.